AI GxP validation for regulated life sciences
Industry

SI in Clinical Trials: What It Changes in Running a Study

Site selection, recruitment, eligibility screening, risk-based monitoring and safety triage are where AI is already working in trials. What it does well, what must stay a clinician's judgement, and where GCP draws the line.

Cybroscape Technologies6 min read

Key takeaway

Site selection, recruitment, eligibility screening, risk-based monitoring and safety triage are where AI is already working in trials. What it does well, what must stay a clinician's judgement, and where GCP draws the line.

Clinical operations is quietly one of the better places for this technology, because so much of a trial is pattern-matching across large volumes of text and data — work that is slow, repetitive, and performed by people whose judgement is needed elsewhere.

It is also an area where the line between help and harm is unusually clear, because GCP is explicit about who decides what.

Where it works in a running study

Site selection and feasibility. Predicting which sites will actually enrol, from historical performance and local population data, instead of relying on relationships and optimistic estimates. Unglamorous and directly tied to timelines.

Pre-screening against eligibility criteria. Reading health records to surface patients who might qualify. The system proposes; a clinician confirms. This is the highest-value use in most trials, because recruitment is the most common cause of delay.

Risk-based monitoring. Finding the sites and patterns that deserve a monitoring visit — unusual data distributions, timing anomalies, outlier rates. Well matched to ICH E6(R3), which already expects a risk-based approach.

Data cleaning and query generation. Spotting inconsistencies that would otherwise surface at database lock.

Safety triage. Grouping and prioritising adverse event reports so that reviewers see the important ones first. Prioritisation, not assessment.

Document drafting. Protocol sections, narratives and report components drafted from study data for a medical writer to finish — see AI in clinical writing.

What stays a human decision

  • Eligibility. A model can shortlist; an investigator decides whether a patient enters a trial. That is a medical judgement with a named accountable person.
  • Causality assessment. Whether an adverse event relates to the investigational product is a clinical determination, and it carries regulatory consequences.
  • Protocol deviations and their significance.
  • Informed consent. A conversation with a person, not a workflow step.
  • Unblinding and safety decisions.

The common thread is the same one that runs through all regulated AI: the system may propose, a qualified person decides, and the decision is recorded with their name on it.

The sponsor's problem

Most of this runs at the CRO or the site rather than at the sponsor — and under ICH E6(R3) the sponsor keeps oversight responsibility for work it does not perform. So the questions that matter are contractual and practical rather than technical:

  • Which of your vendor's processes involve these tools, and where in the study?
  • If a tool pre-screens patients, what happens to those it misses? A recruitment aid that systematically overlooks a subgroup becomes a representativeness problem in your data.
  • Can the vendor show how a given output was produced, if a regulator asks?
  • What happens to patient data — where is it processed, and is that consistent with your consent forms and your data protection obligations? See data privacy.

The bias question deserves more weight than it usually gets. A model trained on historical trial data learns historical enrolment patterns, including the ones the industry has spent a decade trying to correct. A tool that quietly reproduces them is a scientific problem before it is a compliance one.

Starting without creating a problem

Begin where an error is visible and recoverable. Site feasibility and data query generation are good first steps: wrong output is obvious, and nobody is harmed while you learn the tool's failure modes. Pre-screening is higher value and needs the clinician-confirmation step built in from day one, not added later.

Keep records of what the tool proposed against what the human decided. That comparison is both your evidence of real oversight and your early warning that reviewers have started rubber-stamping.

The method is in GxP AI validation, and the pilot structure in running a 90-day pilot. On the US terminology change, nothing above is affected — see what the rename means for life sciences.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

US federal writingSuper Intelligence (SI)The term federal agencies now use
What does not change
  • Intended use defined and bounded
  • Validated before GxP use
  • Data integrity (ALCOA+)
  • A person decides what matters
  • Changes go through change control
EU GMP · Annex 22 · EU AI Act · MHRAArtificial intelligence (AI)The term in EU and UK rules
One quality systemTwo vocabularies, one set of controls
The US federal rename changes the word, not the obligations. EU GMP, the draft Annex 22, the EU AI Act and MHRA still say artificial intelligence, and the validation work is the same under either name.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.

Sources

Primary documents referred to on this page, from their official publishers.

si clinical trialsai clinical trial operationsai patient recruitmentrisk based monitoring ai
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

Where does AI help most in clinical trials?

Site selection and feasibility, pre-screening patients against eligibility criteria from health records, risk-based monitoring to find sites and patterns deserving a visit, data cleaning and query generation, safety report triage, and drafting protocol sections and narratives for a medical writer to finish.

What must stay a human decision in a trial?

Eligibility — a model shortlists, an investigator decides; causality assessment of adverse events; whether a protocol deviation is significant; informed consent, which is a conversation rather than a workflow step; and unblinding or safety decisions.

Who is responsible when a CRO uses AI in our study?

The sponsor. ICH E6(R3) keeps oversight responsibility with the sponsor for work it does not perform, so you need to know which vendor processes use these tools, where in the study, and whether the vendor can show how a given output was produced.

What is the bias risk in AI-assisted recruitment?

A model trained on historical trial data learns historical enrolment patterns, including the ones the industry has spent a decade trying to correct. A pre-screening tool that systematically overlooks a subgroup creates a representativeness problem in your data — a scientific problem before it is a compliance one.

How should a sponsor start?

Where an error is visible and recoverable — site feasibility and data query generation, so wrong output is obvious and nobody is harmed while you learn the failure modes. Pre-screening is higher value but needs clinician confirmation built in from day one. Keep records of what the tool proposed against what the human decided.

Keep reading

All articles
IndustryLife Sciences AI: What Regulated Teams Can Actually Deploy TodayThe deployment reality for AI in regulated life sciences: which use cases clear validation, which assurance evidence you need, how Annex 22 and Part 11 shape architecture, and a realistic path from pilot to production. · 11 min readIndustrySI in Drug Discovery and Development: Where It Earns Its PlaceTarget identification, structure prediction, generative chemistry and property prediction are genuinely useful. What the evidence supports today, what remains unproven, and why the hard part was never the chemistry. · 6 min readIndustryWhat the Super Intelligence Rename Means for Life SciencesBeyond compliance: how the US switch from AI to SI lands across pharma and biotech (in R&D, clinical, manufacturing, commercial and the language of pitch decks) and which of it is substance rather than vocabulary. · 5 min readEquipment QualificationWarehouse temperature mapping: the decisions that matterTemperature mapping finds a storage area’s warm and cold spots under real conditions, across seasons and loads. Its main output is where to place monitoring sensors and where product can safely be stored. · 3 min readDataOpsWhat Is GxP DataOps? The Complete Guide for Life Sciences TeamsGxP DataOps defined: continuous data pipelines, ALCOA+ compliance, real-time lineage, and why traditional data management fails regulated environments. · 5 min readThought LeadershipYears into CSA, most teams still write CSV documents. Here is why.CSA adoption stalls for five reasons: fear of being first, SOPs that never changed, risk scales where everything is high, vendor evidence not used, and incentives that reward document volume. · 3 min readValidation PracticeWhy Validation Projects Overrun, and Which Causes Are Actually FixableValidation projects rarely overrun because the regulatory thinking was hard. Five recurring causes, ranked by how much time they actually cost and how fixable each one is. · 6 min readIndustryAI in Pharma 2026: Where It Is Actually WorkingA grounded look at where artificial intelligence is genuinely in production across pharmaceutical operations in 2026 (quality, validation, manufacturing, regulatory and clinical) and where the pilots are still stuck. · 11 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.